ANGLE plc (ANPCF)
- Previous Close
0.1964 - Open
0.1610 - Bid --
- Ask --
- Day's Range
0.1610 - 0.1610 - 52 Week Range
0.1320 - 0.5200 - Volume
40,600 - Avg. Volume
18 - Market Cap (intraday)
74.393M - Beta (5Y Monthly) 0.10
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1100 - Earnings Date May 20, 2024 - May 21, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.
angleplc.com173
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: ANPCF
Performance Overview: ANPCF
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ANPCF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ANPCF
Valuation Measures
Market Cap
67.69M
Enterprise Value
45.40M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
18.10
Price/Book (mrq)
1.03
Enterprise Value/Revenue
19.71
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.07%
Return on Equity (ttm)
-69.68%
Revenue (ttm)
1.82M
Net Income Avi to Common (ttm)
-22.28M
Diluted EPS (ttm)
-0.1100
Balance Sheet and Cash Flow
Total Cash (mrq)
22.16M
Total Debt/Equity (mrq)
14.26%
Levered Free Cash Flow (ttm)
-11.26M
Research Analysis: ANPCF
Company Insights: ANPCF
ANPCF does not have Company Insights